Cargando…

SARS-CoV-2 spike S2-specific neutralizing antibodies

Since the onset of the coronavirus disease 2019 (COVID-19), numerous neutralizing antibodies (NAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed and authorized for emergency use to control the pandemic. Most COVID-19 therapeutic NAbs prevent the S1 subunit...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Chia-Jung, Chang, Shih-Chung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10274517/
https://www.ncbi.nlm.nih.gov/pubmed/37254830
http://dx.doi.org/10.1080/22221751.2023.2220582

Ejemplares similares